Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CSLCSLLY -1.15%63 3-Year FCF Growth Rate is 33.10% as of Jun. 2026, which is 142% above its 10-year median of 13.70. GuruFocus rates CSLLY with a GF Score™ of 63/100 and a GF Value™ of $47.41 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 1,111 Biotechnology companies, CSL ranks better than 68.77% on this metric.
During the past 12 months, CSL's average Free Cash Flow per Share Growth Rate was -17.90% per year.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 33.10% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 9.80% per year.
During the past 10 years, the average Free Cash Flow per Share Growth Rate was 17.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of CSL was 315.80% per year. The lowest was -38.00% per year. And the median was 13.70% per year.
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
CSL 3-Year FCF Growth Rate Related Terms
CSLLY vs VRTX, REGN, RVMD: 3-Year FCF Growth Rate Comparison
For the Biotechnology subindustry, CSL's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSL 3-Year FCF Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CSL's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where CSL's 3-Year FCF Growth Rate falls into.
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
What does a 3-Year FCF Growth Rate of 33.10% mean?
CSL (CSLLY) has a 3-Year FCF Growth Rate of 33.10% as of Jun. 2026. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for CSL and its competitors. This is 142% above median its historical median of 13.70. According to the industry distribution chart, CSL ranks #347 out of 1111 companies in the Biotechnology industry, placing it in the top 31.2%.
Is CSL's 3-Year FCF Growth Rate too high?
CSL's current 3-Year FCF Growth Rate of 33.10% is 142% above median its 10-year median of 13.70. The Biotechnology industry median 3-Year FCF Growth Rate is 19.30. CSL's value of 33.10% is 71.5% above this industry median. Based on the distribution chart, CSL ranks #347 out of 1111 companies in the Biotechnology industry, which is above the industry midpoint. Overall, CSL has a GF Score™ of 63/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's 3-Year FCF Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CSL ranks #347 out of 1111 companies for 3-Year FCF Growth Rate. This puts CSL in the upper half of its industry. The industry median 3-Year FCF Growth Rate is 19.30. CSL's value of 33.10% is 71.5% above this benchmark. While the company's 10-year median is 13.70 vs. the industry median of 19.30, CSL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year FCF Growth Rate for a Biotechnology company?
The median 3-Year FCF Growth Rate among Biotechnology companies is 19.30, based on 1,111 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year FCF Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year FCF Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CSL's current 3-Year FCF Growth Rate of 33.10% is 71.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year FCF Growth Rate mean?
A high 3-Year FCF Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for CSL and its competitors. For the Biotechnology industry, the median 3-Year FCF Growth Rate is 19.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CSL's current 3-Year FCF Growth Rate is 33.10%, which is 142% above median its own 10-year median of 13.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (CSLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $47.41, compared to a current price of $31.00 — trading 34.6% below its estimated fair value. The current 3-Year FCF Growth Rate is 33.10%, which is 142% above median its 10-year median of 13.70 and 71.5% above the Biotechnology industry median of 19.30. CSL's overall GF Score™ is 63/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year FCF Growth Rate calculated?
3-Year FCF Growth Rate is calculated from a company's financial statements. For CSL (CSLLY), the current 3-Year FCF Growth Rate is 33.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSL (CSLLY) Overvalued in 2026?
Based on GuruFocus' analysis, CSL stock appears to be undervalued.
The current stock price of $31.00 is trading 34.6% below its estimated GF Value™ of $47.41.
GuruFocus considers CSL to be Significantly Undervalued.
Key valuation signals for CSLLY:
3-Year FCF Growth Rate: 33.10% (142% above median its 10-year median of 13.70)
GF Value™: $47.41 vs. price of $31.00 (34.6% below fair value)
Industry Position: 71.5% above the Biotechnology median (#347 of 1111)
No single metric tells the full story. See the CSLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
63GF Score
Get the complete analysis for CSLLY
3-Year FCF Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSLLY has been successfully added to your 
